Weekly count of FDA drug application approvals (NDA/ANDA/BLA) pulled live from openFDA's free, keyless drugsfda endpoint. This is the genuine alt-data differentiator for healthcare: regulatory tailwind/headwind across the industry, sourced the same way analysts manually track FDA press releases, but live and aggregated instead. PCS is moderate, not high — this is industry-wide approval cadence, not a single company's pipeline, so the read-through to any one stock is noisier than a company-specific catalyst.

Aggregate approval velocity reflects FDA throughput and regulatory posture — a slowdown (e.g. during a government shutdown or leadership transition) creates industry-wide pipeline delay risk; a pickup signals smoother regulatory conditions for the whole sector's news flow.

Factor family	Capex & Technology
Relative weight	Core
Update cadence	Weekly
Modeled lead	~4 weeks (a modeling assumption, not a validated finding)
Data source	FDA

The lead time above is a design assumption, not an out-of-sample-validated relationship for a specific security or index. This is one Capex & Technology input among 47; it measures macro context, not a full investment thesis.

LLY · NVO · REGN · VRTX · PFE · MRK · BMY · GILD · AMGN · XBI

Date	Score	Status
2026-09-06	52/100	● Neutral
2026-09-05	52/100	● Neutral
2026-09-04	45/100	● Neutral
2026-09-03	45/100	● Neutral
2026-09-02	46/100	● Neutral
2026-09-01	46/100	● Neutral
2026-08-31	46/100	● Neutral

Scores are derived from macro signals (FRED, EIA, SEC filings, FINRA short interest) and updated as new data arrives. This is not financial advice. Past signal accuracy does not guarantee future results.
unstructuredalpha.com · Not financial advice